Proof of Concept for the Inhibition of Foot-and-Mouth Disease Virus Replication by the Anti-Viral Drug 2'-C-Methylcytidine in Severe Combined Immunodeficient Mice

Transboundary and Emerging Diseases

Volumn 61, Issue 6, 2014, Pages e89-e91

  Lefebvre, D J ^a   De Vleeschauwer, A R ^a   Goris, N ^b   Kollanur, D ^b   Billiet, A ^b   Murao, L ^b   Neyts, J ^b,c   De Clercq, K ^a  

^a VETERINARY AND AGROCHEMICAL RESEARCH CENTRE   (Belgium)

^b Okapi Sciences NV   (Belgium)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

2' C methylcytidine; Anti viral drugs; Foot and mouth disease; Foot and mouth disease virus; Proof of concept; Severe combined immunodeficient mice

Indexed keywords

FOOT-AND-MOUTH DISEASE VIRUS; MUS;

2'-C-METHYLCYTIDINE; ANTIVIRUS AGENT; CYTIDINE; VIRUS RNA;

ANALOGS AND DERIVATIVES; ANIMAL; DISEASE MODEL; DRUG EFFECTS; FOOT AND MOUTH DISEASE VIRUS; FOOT-AND-MOUTH DISEASE; MOUSE; SCID MOUSE; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; CYTIDINE; DISEASE MODELS, ANIMAL; FOOT-AND-MOUTH DISEASE; FOOT-AND-MOUTH DISEASE VIRUS; MICE; MICE, SCID; RNA, VIRAL;

EID: 84911373368     PISSN: 18651674     EISSN: 18651682     Source Type: Journal    
DOI: 10.1111/tbed.12069     Document Type: Article

References (14)

1. Chen, W., M. Liu, Y. Jiao, W. Yan, X. Wei, J. Chen, L. Fei, Y. Liu, X. Zuo, F. Yang, Y. Lu and Z. Zheng, 2006: Adenovirus-mediated RNA interference against foot-and-mouth disease virus infection both in vitro and in vivo. J. Virol. 80, 3559-3566.
2. Clark, J. L., L. Hollecker, J. C. Mason, L. J. Stuyver, P. M. Tharnish, S. Lostia, T. R. McBrayer, R. F. Schinazi, K. A. Watanabe, M. J. Otto, P. A. Furman, W. J. Stec, S. E. Patterson and K. W. Pankiewicz, 2005: Design, synthesis, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methylcytidine, a potent inhibitor of hepatitis C virus replication. J. Med. Chem. 48, 5504-5508.
3. Dias, C. C., M. P. Moraes, M. Weiss, F. D. Segundo, E. Perez-Martin, A. M. Salazar, T. de los Santos and M. J. Grubman, 2012: Novel antiviral therapeutics to control foot-and-mouth disease. J. Interferon Cytokine Res. 32, 462-473.
4. Duan, J., W. Paris, P. Kibler, C. Bousquet, M. Liuzzi and M. G. Cordingley, 1998: Dose and duration-dependence of ganciclovir treatment against murine cytomegalovirus infection in severe combined immunodeficient mice. Antiviral Res. 39, 189-197.
5. Furuta, Y., K. Takahashi, K. Shiraki, K. Sakamoto, D. F. Smee, D. L. Barnard, B. B. Gowen, J. G. Julander and J. D. Morrey, 2009: T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 82, 95-102.
6. Golde, W. T., J. M. Pacheco, H. Duque, T. Doel, B. Penfold, G. S. Ferman, D. R. Gregg and L. L. Rodriguez, 2005: Vaccination against foot-and-mouth disease virus confers complete clinical protection in 7 days and partial protection in 4 days: use in emergency outbreak response. Vaccine 23, 5775-5782.
7. Goris, N., A. De Palma, J. F. Toussaint, I. Musch, J. Neyts, and K. De Clercq, 2007: 2'-C-methylcytidine as a potent and selective inhibitor of the replication of foot-and-mouth disease virus. Antiviral Res. 73, 161-168.
8. Goris, N., F. Vandenbussche and K. De Clercq, 2008: Potential of antiviral therapy and prophylaxis for controlling RNA viral infections of livestock. Antiviral Res. 78, 170-178.
9. Goris, N., F. Vandenbussche, C. Herr, J. Villers, Y. Van der Stede and K. De Clercq, 2009: Validation of two real-time RT-PCR methods for foot-and-mouth disease diagnosis: RNA-extraction, matrix effect, uncertainty of measurement and precision. J. Virol. Methods 160, 157-162.
10. Julander, J. G., A. K. Jha, J. A. Choi, K. H. Jung, D. F. Smee, J. D. Morrey and C. K. Chu, 2010: Efficacy of 2'-C-methylcytidine against yellow fever virus in cell culture and in a hamster model. Antiviral Res. 86, 261-267.
11. Kim, S. M., J. H. Park, K. N. Lee, S. K. Kim, Y. J. Ko, H. S. Lee and I. S. Cho, 2012: Enhanced inhibition of foot-and-mouth disease virus by combinations of porcine interferon-α and antiviral agents. Antiviral Res. 96, 213-220.
12. Lefebvre, D. J., J. Neyts and K. De Clercq, 2010: Development of a foot-and-mouth disease infection model in severe combined immunodeficient mice for the preliminary evaluation of antiviral drugs. Transbound. Emerg. Dis. 57, 430-433.
13. Perez-Martin, E., M. Weiss, F. Diaz-San Segundo, J. M. Pacheco, J. Arzt, M. J. Grubman and T. de los Santos, 2012: Bovine type III interferon significantly delays and reduces the severity of foot-and-mouth disease in cattle. J. Virol. 86, 4477-4487.
14. Ribbens, S., N. Goris, J. Neyts and J. Dewulf, 2012: Classical swine fever outbreak containment using antiviral supplementation: a potential alternative to emergency vaccination and stamping-out. Prev. Vet. Med. 106, 34-41.